摘要
背景与目的晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)化疗处于瓶颈,抗血管靶向治疗逐渐显示优势。本文研究重组人血管内皮抑素(rh-Endostin,恩度YH-16)联合化疗靶向治疗晚期非小细胞肺癌的临床疗效、毒性反应和对生活质量的影响。方法62例晚期非小细胞肺癌患者随机分为2组:血管内皮抑素组32例采用重组人血管内皮抑素加一线化疗方案,对照组30例仅选用一线化疗方案。2个周期后评价近期临床有效率、临床受益率以及生活质量的改善程度,同时观察毒副作用。结果血管内皮抑素组临床有效率为46.87%,临床受益率为81.25%,而对照组分别为26.66%和53.33%。两组有效率尚不具有统计学意义(χ2=1.912,P=0.166),但两组受益率差异明显,具有统计学意义(χ2=4.3185,P=0.0377)。对照组和血管内皮抑素组进行治疗后生活质量(QoL)均有所改善,血管内皮抑素组则更为明显,二者相比差异具有统计学意义(χ2=11.233,P=0.0008)。治疗后患者所发生的毒性反应为恶心、呕吐,骨髓抑制,周围神经毒性,主要为化疗所致的副反应,两组在这些方面差异无统计学意义(P>0.05)。血管内皮抑素组有3例感觉心前胸不适,出现心电图改变,表现为ST-T轻微下移,给予对症治疗后消失,但两组比较差异无统计学意义(χ2=1.2701,P=0.2597)。结论血管内皮抑素未增加化疗的毒副作用,临床应用安全,耐受性良好;血管内皮抑素联合化疗药物对晚期NSCLC具有较好的疗效,尤其在改善病人生存质量方面具有优势。
Background and objective The chemotherapy of advanced non-small cell lung cancer is in a Bottleneck. The target therapy of Anti-angiogenesis gradually shows an advantage in the therapy of patients with advanced NSCLC. To investigate the short-term efficacy, safety and the quality of life of the target therapy of rh-Endostin combined with chemotherapy in patients with advanced NSCLC. Methods Sixty-two advanced NSCLC patients were randomly divided into either the trial group with chemotherapy plus rh-Endostin or control group with chemotherapy alone. The efficacy and toxicity were evaluated after 2 cycles according to RECIST criteria. Results The trial groups efficiency rate was 46.87%, while the control group was 26.66%, there was no significant differences of two groups （χ2= 1.912, P=0.166）. The clinical benefit rate was 81.25% in the trial group and 53.33% in control group. There was significant difference of the clinical benefit rate between the trial group and the control group （χ2=4.3185, P=0.0377）. The score of quality of life in the trial group was significantly higher than that the control group after the treatment （χ2=11.233, P=0.0008）. There was no significant difference of incidence of toxicities between the trial group and the control group （P〉0.05）. Conclusion Rh-Endostin combined with chemotherapy was effective, reasonable, safe and well tolerated for advanced NSCLC.
出处
《中国肺癌杂志》
CAS
2009年第7期780-784,共5页
Chinese Journal of Lung Cancer
